Basics Eagle Pharmaceuticals, Inc. Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. IPO Date: February 12, 2014 Sector: Healthcare Industry: Drug Manufacturers Activated in VL: True Average Daily Range Avg Daily Range: $0.99 | 7.65% Avg Daily Range (30 D): $0.54 | 24.04% Avg Daily Range (90 D): $0.57 | 24.42% Institutional Daily Volume Avg Daily Volume: .17M Avg Daily Volume (30 D): M Avg Daily Volume (90 D): M Trade Size Avg Trade Size (Sh.): 80 Avg Trade Size (Sh.) (30 D): 918 Avg Trade Size (Sh.) (90 D): 316 Institutional Trades Total Inst.Trades: 2,324 Avg Inst. Trade: $1.52M Avg Inst. Trade (30 D): $1M Avg Inst. Trade (90 D): $1M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $.76M Avg Closing Trade (90 D): $.76M Avg Closing Volume: 31.5K     News Oct 6, 2025 @ 11:30 PM Eagle Pharmaceuticals Announces Availability of Un... Source: Na Aug 28, 2025 @ 11:30 PM Eagle Pharmaceuticals to Appoint Abhinav Jain to i... Source: Na Oct 14, 2024 @ 10:13 PM Snowflake, Eagle Pharmaceuticals, Blue Ridge Banks... Source: Johnson Fistel, Llp Oct 10, 2024 @ 5:00 PM Global Antiemetics Drugs Market to Exhibit Growth ... Source: Delveinsight May 22, 2024 @ 1:00 PM Eagle Pharmaceuticals Announces Receipt of Delisti... Source: Eagle Pharmaceuticals, Inc. Financials   TTM Q2 2023 Q1 2023 Basic EPS $.92 $.39 $.44 Diluted EPS $.91 $.39 $.44 Revenue $ 257.55M $ 64.65M $ 66.31M Gross Profit $ 184.28M $ 47.79M $ 49.01M Net Income / Loss $ 11.95M $ 5.16M $ 5.75M Operating Income / Loss $ 41.01M $ 10.3M $ 11.77M Cost of Revenue $ 73.27M $ 16.86M $ 17.3M Net Cash Flow $ -21.21M $ -6.54M $ -33.42M PE Ratio